188 related articles for article (PubMed ID: 37679351)
1. Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis.
Chan WL; Chong VCL; Wee IJY; Poon LM; Chan EHL; Lee J; Chee YL; Jeyasekharan AD; Chng WJ; Samuel M; de Mel S
Blood Cancer J; 2023 Sep; 13(1):140. PubMed ID: 37679351
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
3. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
[TBL] [Abstract][Full Text] [Related]
4. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
Kapoor P; Paludo J; Abeykoon JP
Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Adam Z; Krejčí M; Pour L; Ševčíková E
Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
[TBL] [Abstract][Full Text] [Related]
6. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Kim JL; Gerrie AS; Savage KJ; Villa D; Scott D; Craig JW; Farinha P; Skinnider B; Slack G; Connors JM; Sehn LH; Venner C; Freeman CL
Leuk Lymphoma; 2024 Mar; 65(3):346-352. PubMed ID: 38156444
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
[TBL] [Abstract][Full Text] [Related]
9. How we manage patients with Waldenström macroglobulinaemia.
Simon L; Baron M; Leblond V
Br J Haematol; 2018 Jun; 181(6):737-751. PubMed ID: 29637541
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia.
de Tute R; Counsell N; Clifton-Hadley L; D'Sa S; Pratt G; Campbell G; Campbell L; Sadler R; Townsend W; Popova B; Smith P; Schofield O; Owen R; Auer R
Leukemia; 2024 Apr; 38(4):822-828. PubMed ID: 38409530
[TBL] [Abstract][Full Text] [Related]
11. Waldenstrom macroglobulinemia: prognosis and management.
Oza A; Rajkumar SV
Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
Lim KJC; Tam CS
Expert Opin Pharmacother; 2020 Sep; 21(13):1555-1564. PubMed ID: 32603202
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
16. Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials.
Santos-Lozano A; Morales-Gonzalez A; Sanchis-Gomar F; Cristi-Montero C; Fiuza-Luces C; Pareja-Galeano H; Martínez-López J; Garatachea N; Lucia A
Crit Rev Oncol Hematol; 2016 Sep; 105():118-26. PubMed ID: 27423974
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
[TBL] [Abstract][Full Text] [Related]
18. [Waldenström macroglobulinaemia].
Simon L; Leblond V
Rev Prat; 2018 Sep; 68(7):797-802. PubMed ID: 30869336
[TBL] [Abstract][Full Text] [Related]
19. [Waldenström's macroglobulinemia].
Watanabe R
Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
[TBL] [Abstract][Full Text] [Related]
20. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
